After dropping its only clinical-stage candidate last month, ADC Therapeutics is shutting down a U.K. R&D site and laying off 30% of its workforce. More: ADC Therapeutics shutters UK R&D site, culls several preclinical programs and trims workforce by 30%
read moreBelgium’s UCB is adding its name to the mix of drugmakers planning to grow their manufacturing footprints in the U.S. More: UCB touts plan for 'major' US investment to boost biologics capacity Source: fierce
read moreFor the second time in nine months, a Delaware judge has sided with Syntimmune shareholders over AstraZeneca, granting a $181 million award. The decision comes on top of a $130 million judgment issued in September of last year. More: AstraZeneca
read moreCobenfy, the novel antipsychotic drug that Bristol Myers Squibb obtained from a $14 billion acquisition, could have a problem following a phase 3 flop and “moderating” new-to-brand prescription growth. But the company’s top executives don’t see things that way. More:
read moreSprout Pharmaceuticals is once again under fire from the FDA’s Office of Prescription Drug Promotion. More: Sprout hit with FDA warning letter over CEO’s Instagram post about female libido drug Addyi Source: fierce
read more
Biotech firm shares phase 2 findings on novel osteoarthritis treatmen More: Levicept presents new LEVI-04 data at EULAR Source: News
read more© 1994 - 2025 B.M. Pharmaceuticals